Tatsuhiro Fujimiya

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Squamous Cell Carcinoma

Tyrosine Kinase

Ejection Fraction

Chronic Myeloid Leukemia

Top Venues

Journal of pharmaceutical health care and sciences

American journal of therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Tatsuhiro Fujimiya, Kanako Azuma, Yuki Togashi, Koji Kuwata, Sakae Unezaki, Hironori Takeuchi
Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. Journal of pharmaceutical health care and sciences 10 (1) (2024)
Tatsuhiro Fujimiya, Kanako Azuma, Yuki Togashi, Koji Kuwata, Sakae Unezaki, Hironori Takeuchi
Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. Journal of pharmaceutical health care and sciences 10 (1) (2024)
Tatsuhiro Fujimiya, Kanako Azuma, Yuki Togashi, Koji Kuwata, Sakae Unezaki, Hironori Takeuchi
Pembrolizumab-induced secondary adrenal insufficiency due to adrenocorticotrophic hormone deficiency in a patient with non-small-cell lung carcinoma: a case report. Journal of pharmaceutical health care and sciences 10 (1) (2024)
Takehiko Tsuno, Tatsuhiro Fujimiya, Takashi Kawaguchi, Ryota Yanaizumi, Keiko Kojima, Akime Miyasato, Kanako Azuma, Tomoya Saeki, Hironori Mawatari, Takashi Igarashi, Tomofumi Miura, Hiroyuki Ogura, Junichi Kondo, Tadashi Tanoue, Hiroshi Hamada, Yu Oyama, Akira Kotani, Takuhiro Yamaguchi, Hideki Hakamata
Psychological barriers to the use of opioid analgesics for treating pain in patients with advanced recurrent cancer (BAROC): protocol for a multicentre cohort study. BMJ open 12 (3) (2022)
Tatsuhiro Fujimiya, Hideki Sugita, Masaoki Kin, Haruki Funakoshi, Yutaro Kubota, Takuya Tsunoda
Case of Imatinib Susceptibility to CYP3A4-Mediated Drug-Drug Interactions in a Patient With Gastrointestinal Stromal Tumor. American journal of therapeutics (2022)